http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106755025-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2795-10121 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-76 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2016-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106755025-B |
| titleOfInvention | Preparation method of recombinant T4 phage displaying VEGFR-2 |
| abstract | The invention belongs to the technical field of medical engineering, and particularly relates to a preparation method of a recombinant T4 bacteriophage capable of displaying VEGFR-2 protein on the surface. Firstly, a recombinant plasmid carrying VEGFR-2 extracellular region fragment is constructed, then escherichia coli BL21 is transformed, and lysozyme-deficient phage T4e is utilized ‑ Infecting Escherichia coli BL21 to make T4e ‑ And carrying out homologous recombination on the phage to finally obtain the recombinant T4 phage with the VEGFR-2 protein displayed on the surface. Preliminary experiments show that the obtained recombinant T4 bacteriophage maintains better biological activity, has the biological activity of binding to VEGF and inhibiting the function thereof, and can be used for treating various diseases related to vascular proliferation including tumors. The recombinant phage can prevent the combination of VEGF and VEGFR-2, has obvious anti-tumor angiogenesis activity and has good application prospect. |
| priorityDate | 2016-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 368.